Malladi Drugs

What Malladi Drugs does

Malladi Drugs & Pharmaceuticals Ltd is an India-based, privately held Active Pharmaceutical Ingredient (API) manufacturer founded in 1980 and headquartered in Chennai, Tamil Nadu. The company specializes in the production of niche APIs — primarily Ephedrine salts, Pseudoephedrine, Phenylephrine HCL, and Phenylephrine bi-tartrate — where it claims leading global market share verified by the United States Pharmacopeia (USP). Its manufacturing capabilities also extend to pharmaceutical intermediates, chiral building blocks for enantiomerically pure drugs, specialty chemicals, and custom chemistry services for drug discovery including CMC dossier preparation.

The company's technology platform is built on advanced synthetic chemistry, with a state-of-the-art R&D center near Chennai focused on new drug development and process enhancement. Regulatory credentials are a core competency: Malladi holds 22 Drug Master Files with the US FDA and has secured approvals from EDQM (Europe), ANSM (France), KFDA (Korea), and TGA (Australia), along with CEP certifications for key products. This regulatory portfolio enables direct B2B supply of APIs and intermediates to pharmaceutical companies across 60+ countries.

Commercially, Malladi operates as a B2B contract manufacturer selling APIs and intermediates to global pharmaceutical customers through direct sales relationships. Pricing is negotiated on a contract basis rather than publicly disclosed. In April 2022, the company received a Rs 250 crore (approximately USD 32.7 million) growth equity investment from InvAscent to fund expansion and new product launches. The company maintains sustainability initiatives including zero liquid discharge and renewable energy use, and employs 501-1,000 staff across its operations.

Name

Malladi Drugs

Legal name

Malladi Drugs & Pharmaceuticals Ltd

Website

https://malladi.co.in

Company type

Private

Founded year

1980

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Malladi Drugs & Pharmaceuticals Ltd is a Chennai, India-based API manufacturer founded in 1980 that produces Ephedrine, Pseudoephedrine, and Phenylephrine APIs (where it holds leading global market share), pharmaceutical intermediates, and chiral building blocks, supplying pharmaceutical companies across 60+ countries from FDA-approved facilities.

Ownership category

akta.pro rank

Product category

Pharmaceutical API Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

akta.pro secondary industries

Controlled Substances / DEA-Scheduled API Manufacturing (HLAGAHAD), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Active pharmaceutical ingredients
• Pharmaceutical intermediates
• Chiral building blocks
• API manufacturing
• Specialty chemicals

Headquarters

HQ city

Carlstadt

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel, Infrastructure

Distribution channels1 record

Marketing channels3 records

Core offering

Malladi Drugs & Pharmaceuticals Ltd manufactures Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, chiral building blocks, and specialty chemicals for pharmaceutical companies worldwide. The company holds a leading global market share in Phenylephrine HCL, Phenylephrine Bi-Tartrate, and Pseudoephedrine APIs (verified by USP), and supplies products to over 60 countries from FDA-approved facilities. It also provides custom chemistry services for drug discovery and CMC dossier preparation.

Product overview

Malladi Drugs & Pharmaceuticals Ltd is a pharmaceutical manufacturing company that produces a portfolio of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, chiral building blocks, and specialty chemicals. The company operates as a single unified manufacturing operation with specialized product lines centered around its core Ephedrine and Pseudoephedrine franchise and Phenylephrine franchise. Key products include Phenylephrine HCL, Phenylephrine Bi-Tartrate, Pseudoephedrine, and Ephedrine Salts. The company differentiates through leading global market share in Phenylephrine and Pseudoephedrine, verified by USP, and complements its product portfolio with custom chemistry services for drug discovery and CMC dossier preparation.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs) High-quality Active Pharmaceutical Ingredients across a wide therapeutic range, with extensive manufacturing capacity and rigorous quality control meeting the highest standards for pharmaceutical companies worldwide.
• Phenylephrine HCL Active Pharmaceutical Ingredient produced by Malladi, serving pharmaceutical companies worldwide. Malladi is a leading global market share producer of Phenylephrine.
• Phenylephrine Bi-Tartrate Active Pharmaceutical Ingredient with leading global market share, verified by USP for top-tier quality.
• Pseudoephedrine Active Pharmaceutical Ingredient with leading global market share in both Pseudoephedrine and Ephedrine salts, verified by USP for top-tier quality, serving over 60 countries.
• Ephedrine Salts Top-tier Active Pharmaceutical Ingredients including Ephedrine salts, delivered to over 60 countries from FDA-approved facilities.
• Pharmaceutical Intermediates Essential intermediates for the synthesis of complex pharmaceuticals, produced using advanced manufacturing techniques and stringent quality measures, integral to drug development and production.
• Chiral Building Blocks Chiral building blocks crucial for creating enantiomerically pure drugs, produced in state-of-the-art facilities with innovative processes ensuring the highest purity and quality.
• Specialty Chemicals Specialty chemicals manufactured across various therapeutic categories, supporting pharmaceutical advancements and therapeutic efficacy.
• Custom Chemistry for Drug Discovery Custom chemistry services for drug discovery, full compliance in development, and CMC dossier preparation supporting pharmaceutical development.

Quantifiable outcome

• Supplying to 60+ countries globally
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Divis Laboratories: Indian API manufacturer with a comparable focus on small-molecule APIs, intermediates, and custom synthesis for global pharma customers. Similar scale, regulatory footprint, and B2B go-to-market.
• Jubilant Pharmova: Indian-headquartered API manufacturer and CDMO with multi-decade history, FDA-approved facilities, and DMF presence in major regulated markets. Highly comparable in regulatory depth and customer profile.
• Laurus Labs: Indian API and intermediates manufacturer supplying global generics with comparable FDA/EMA filings and DMF base. Overlapping customer base in regulated generic APIs.
• Aarti Drugs: Indian API and intermediate manufacturer focused on regulated small molecules with comparable DMF strategy and similar customer overlap in generic APIs.
• Cambrex: US/EU-headquartered small-molecule API and CDMO business (owned by Permira). Directly comparable in custom synthesis, regulatory-grade API supply, and CDMO services.
• Piramal Pharma Solutions: India-based CDMO and API manufacturer with FDA-approved facilities, DMFs, and chiral synthesis capabilities. Closely comparable on custom chemistry and CMC dossier services.
• Hikal: Indian API and intermediates manufacturer serving global pharma with similar scale and regulatory filings, including DMFs with FDA and other agencies.
• Ipca Laboratories: Indian API and finished dosage manufacturer with global distribution and similar small-molecule API portfolio addressing regulated generics markets.
• Granules India: Indian API and finished dosage manufacturer serving global regulated markets with comparable DMF/regulatory strategy and customer overlap in generic small molecules.

Broad incumbents

• Aurobindo Pharma: Large Indian vertically integrated generics and API manufacturer. Much bigger in scale, but competes in similar small-molecule API categories and end markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Malladi_Drugs
• LinkedInlinkedin.com/company/malladi-drugs-and-pharmaceuticals-limited

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Malladi Drugs